We’re experiencing issues for some mobile devices with our ARTG dataset filter function. We apologise for any inconvenience while we work to fix this.
ZIRDAWNY (Otsuka Australia Pharmaceutical Pty Ltd)
Product name
ZIRDAWNY
Date registered
Evaluation commenced
Decision date
Approval time
167 (255 working days)
Active ingredients
donidalorsen sodium
Registration type
NCE/NBE
Indication
ZIRDAWNY is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.